WO2003089007B1 - Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu - Google Patents

Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu

Info

Publication number
WO2003089007B1
WO2003089007B1 PCT/IB2003/001197 IB0301197W WO03089007B1 WO 2003089007 B1 WO2003089007 B1 WO 2003089007B1 IB 0301197 W IB0301197 W IB 0301197W WO 03089007 B1 WO03089007 B1 WO 03089007B1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
combination
pharmaceutical composition
flu
decongestant
Prior art date
Application number
PCT/IB2003/001197
Other languages
French (fr)
Other versions
WO2003089007A1 (en
Inventor
Bradley Ryan Parsons
Plessis Erica Lynne Du
Original Assignee
Adcock Ingram Intellectual Pro
Bradley Ryan Parsons
Plessis Erica Lynne Du
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcock Ingram Intellectual Pro, Bradley Ryan Parsons, Plessis Erica Lynne Du filed Critical Adcock Ingram Intellectual Pro
Priority to AU2003219348A priority Critical patent/AU2003219348A1/en
Publication of WO2003089007A1 publication Critical patent/WO2003089007A1/en
Publication of WO2003089007B1 publication Critical patent/WO2003089007B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical composition comprises a combination of a decongestant such as phenylephrine, pseudoephedrine or phenylpropanolamine or a pharmaceutically acceptable salt or derivative thereof, and at least one other active ingredient selected from a non-steriodal anti-inflammatory, an anti-histamine, a local anaesthetic, an antiseptic anaesthetic and a cough suppressant, and a pharmaceutically acceptable carrier. The pharmaceutical composition, which is provided in the form of a lozenge, tablet, capsule, mouthwash, gargle or spray, in particular a lozenge, is suitable for the symptomatic relief of cough and flu, including but not limited to that associated with sore throats and congested nasal passages.

Claims

AMENDED CLAIMS[received by the International Bureau on 25 September 2003 (25.09.03); original claims 1-27 replaced by new claims 1-20 (3 pages)]
1. A pharmaceutical composition comprising a combination of a decongestant and benzydamine HCI or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier.
2. A pharmaceutical composition according to claim 1 , wherein the decongestant is selected from the group comprising phenylephrine, pseudoephedrine and phenylpropanolamine, and pharmaceutically acceptable salts and derivatives thereof.
3. A pharmaceutical composition according to claim 1 or claim 2, further comprising an antiseptic anaesthetic selected from the group comprising chlorhexidine gluconate, povidone iodine, cetylpyridinium chloride, cetalkonium chloride and cetrimide, and pharmaceutically acceptable salts and derivatives thereof.
4. A pharmaceutical composition comprising a combination of a decongestant and an antiseptic anaesthetic selected from the group comprising chlorhexidine gluconate, povidone iodine, cetylpyridinium chloride, cetalkonium chloride and cetrimide, and pharmaceutically acceptable salts and derivatives thereof.
5. A pharmaceutical composition according to claim 4, wherein the decongestant is selected from the group comprising phenylephrine, pseudoephedrine and phenylpropanolamine, and pharmaceutically acceptable salts and derivatives thereof
6. A pharmaceutical composition according to claim 4 or claim 5, further comprising benzydamine HCI or a pharmaceutically acceptable salt or derivative thereof. 17
7. A pharmaceutical composition according to any one of claims 1 to 6, which is provided in the form of a lozenge, tablet, capsule, mouthwash, gargle or spray.
8. A combination as defined in any one of claims 1 to 6 for use in a method of providing symptomatic relief of cough and/or flu, comprising administering to a patient in need thereof a therapeutically effective amount of the combination.
9. A combination according to claim 8, which is administered in a dosage form selected from lozenges, tablets, capsules, mouthwashes, gargles and sprays.
10. A combination according to claim 8 or claim 9, wherein the cough and/or flu is associated with sore throats and/or congested nasal passages.
11. The use of a combination as defined in any one of claims 1 to 6, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment of cough and/or flu.
12. A use according to claim 11 , wherein the medicament is provided in a dosage form selected from lozenges, tablets, capsules, mouthwashes, gargles and sprays.
13. A use according to claim 11 or claim 12, wherein the cough and/or flu is associated with sore throats and/or congested nasal passages.
14. A method of providing symptomatic relief of cough and/or flu, comprising administering to a patient in need thereof a therapeutically effective amount of a combination as defined in any one of claims 1 to 6, and a pharmaceutically acceptable carrier. 18
15. A method according to claim 14, wherein the combination is administered in a dosage form selected from lozenges, tablets, capsules, mouthwashes, gargles and sprays.
16. A method according to claim 14, wherein the combination is administered by nasal or oral administration.
17. A lozenge comprising a combination of a decongestant and benzydamine HCI or a pharmaceutically acceptable salt or derivative thereof and/or an antiseptic anaesthetic.
18. A lozenge according to claim 17, wherein the decongestant is selected from the group comprising phenylephrine, pseudoephedrine and phenylpropanolamine, and pharmaceutically acceptable salts and derivatives thereof.
19. A lozenge according to claim 17 or claim 18, wherein the antiseptic anaesthetic is selected from the group comprising chlorhexidine gluconate, povidone iodine, cetylpyridinium chloride, cetalkonium chloride and cetrimide, and pharmaceutically acceptable salts and derivatives thereof.
20. A pharmaceutical composition comprising a combination of benzydamine HCI, phenylephrine HCI and cetylpyridium chloride, and a pharmaceutically acceptable carrier.
PCT/IB2003/001197 2002-04-22 2003-04-02 Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu WO2003089007A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003219348A AU2003219348A1 (en) 2002-04-22 2003-04-02 Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2002/3159 2002-04-22
ZA200203159 2002-04-22

Publications (2)

Publication Number Publication Date
WO2003089007A1 WO2003089007A1 (en) 2003-10-30
WO2003089007B1 true WO2003089007B1 (en) 2003-12-24

Family

ID=29251519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/001197 WO2003089007A1 (en) 2002-04-22 2003-04-02 Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu

Country Status (2)

Country Link
AU (1) AU2003219348A1 (en)
WO (1) WO2003089007A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI313598B (en) * 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US20050192355A1 (en) * 2004-02-17 2005-09-01 Wyeth Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
EP2497460A1 (en) 2005-03-10 2012-09-12 3M Innovative Properties Co. Methods of reducing microbial contamination
EP1896022B1 (en) 2005-06-17 2012-10-31 AFT Pharmaceuticals Limited Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
GB0525029D0 (en) * 2005-12-08 2006-01-18 Univ Hull Receptor Antagonist
US7754234B2 (en) * 2006-07-12 2010-07-13 Jones Thomas L Composition and method of treating a sore throat
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
GB0722349D0 (en) * 2007-11-15 2007-12-27 Reckitt Benckiser Healthcare Use of anti-bacterial compounds having an anaesthetic effect
CN103385804A (en) * 2013-07-24 2013-11-13 阎昭良 Nano-silver mouth wash for preventing and treating oral diseases and preparation method thereof
WO2016126217A1 (en) * 2015-02-03 2016-08-11 Pharmacti̇ve Ilaç Sanayi̇ Ve Ti̇caret A. Ş. Stable pharmaceutical combination containing benzydamine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3940325C2 (en) * 1989-12-06 1996-02-22 Klaus Woerz Device for scraping roughened surfaces of worktops
ZA944949B (en) * 1993-07-12 1995-04-05 Smithkline Beecham Corp Matrix-entrapped beadlet preparation
IT1274026B (en) * 1994-03-01 1997-07-14 Acraf ANTITOSSE COMPOSITION
IT1274655B (en) * 1995-02-28 1997-07-18 Smithkline Beecham Farma PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-INFLAMMATORY AGENT AND AN ANTI-MICROBIAL AGENT
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
WO1998052545A1 (en) * 1997-05-22 1998-11-26 The Boots Company Plc Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
WO1998052540A1 (en) * 1997-05-22 1998-11-26 The Boots Company Plc Pharmaceutical compositions

Also Published As

Publication number Publication date
WO2003089007A1 (en) 2003-10-30
AU2003219348A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
ES2330873T3 (en) COMPOSITION FOR ORAL DOSAGE OF PROLONGED RELEASE.
US4446140A (en) Method and composition for treating mouth pain
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
EP1444984B1 (en) Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
WO2003089007B1 (en) Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
CA2503810A1 (en) Therapeutic agent for fibromyalgia
SE9901573D0 (en) New compounds
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
US20060105057A1 (en) Compositions using tetrasilver tetroxide and methods for management of skin conditions using same
CA2160874C (en) Nasal aromatic releasing compositions
EP1900378A1 (en) Pharmaceutical compositions for the treatment of fungal infections
WO2002000166A3 (en) New compounds useful as antibacterial agents
JP4824954B2 (en) Oral composition for the treatment of stomatitis
CA2489315A1 (en) Formulation of nefopam and its use in the treatment of pain
US4892877A (en) Antitussive liquid compositions containing phenol
JP5019724B2 (en) Antifungal pharmaceutical composition
US8148425B2 (en) Pharmaceutical composition containing phloroglucinol and paracetamol
JP4799957B2 (en) Pharmaceutical composition for the treatment of stomatitis
WO2000066550A8 (en) New compounds
EP2892528B1 (en) Pharmaceutical compositions comprising flurbiprofen
PL168968B1 (en) Method of manufacturing an antitussive drug
CA2076149A1 (en) Potentiation of antitussive effect of dextromethorphan
US20040022868A1 (en) Compositions using tetrasilver tetroxide and methods for management of skin conditions using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

B Later publication of amended claims

Free format text: 20030925

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP